News | June 01, 2026
Indoco's formulation plant at Baddi receives EU GMP certification
This certification confirms that the facility complies with Good Manufacturing Practice requirements as referred in the EC Directive
This certification confirms that the facility complies with Good Manufacturing Practice requirements as referred in the EC Directive
On a full-year basis, revenue from operations for FY26 grew 18.9 percent year-on-year to Rs 827.87 crore compared to Rs 696.48 crore in FY25
The acquisition marks Anupam Rasayan’s strategic entry into the pharmaceutical formulations segment
The approval was granted by Agenzia Italiana del Farmaco
Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
Doshi has established a strong track record in driving quality assurance, regulatory compliance, and formulation excellence across complex pharmaceutical operations
Next-generation berberine formulation developed with BioSOLVE Technology targets metabolic health, blood sugar balance, and weight management
Antiviral injection addressing CMV and HSV infections had US market sales of nearly $15 million in the last 12 months
Famotidine Injection USP is a generic version of Pepcid injection to be manufactured at its Nagpur facility for the U.S. market
The certification follows an inspection conducted by the Malta Medicines Authority between January 29, 2026, and February 3, 2026
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
